en · de · es · fr · pt
aod-9604-notes.peptides9000.com › Data › Mechanism And Regulatory Status — Research Overview

Mechanism And Regulatory Status — Research Overview

By Editorial Desk · published 2026-04-13 · last reviewed 2026-05-23 · Data

This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Aod-9604 at a glance

PropertyValueNotes
Typical storage temperature-20 °CLyophilized peptide; protect from moisture and light.
Typical analytical methodHPLC and mass spectrometryUsed to confirm identity and estimate purity.
Common synonymsAOD9604; hGH 176-191Naming varies by supplier and publication.
Disulfide bondsOneAffects folded structure and stability.
Typical research purity≥95%Value depends on supplier and analytical method.

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Related pages on this site

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Background and Molecular Identity

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Background from the literature

Also known as anabolic steroid precursors, they promote lean body mass. Once in the body, these precursors are converted to testosterone and increase endogenous testosterone. The desired effects of steroid precursors however, are often not seen as they do not bind well to androgen receptors. Examples of prohormones include norandrostendione, androstenediol, and dehydroepiandrosterone (DHEA). These steroids have little desired effect compared to anabolic steroids, but have the same side effects. Androstenedione in 2005 became classified as a controlled substance by WADA, however DHEA can still be obtained legally as an over-the-counter nutritional supplement.

== The document == The document was presented to the British Museum in 1924 by Walter Rothschild; today it is held in the British Library, which separated from the British Museum in 1973, as Additional Manuscripts number 41178. From October 1987 to May 1988 it was lent outside the UK for display in Israel's Knesset.

==== Sulfur and lightning ==== Sulfur’s role as a symbol of divine wrath and punishment may come from its association with lightning. For centuries, lightning was thought to cause a sulfur smell when it struck, and was therefore linked with it, including in religious contexts. In the 12th century, the Byzantine scholar John Tzetzes discussed the different associations around the word theion in his Chiliades, mentioning different meanings such as sulfur, incense (which he links to the breath of the immortals) and thunder, as well as it referring to "bewildering" and "amazing" things, the stars, souls, and angels. He explains that thunder is divine fire, and that it gives off a strong smell resembling sulfur. Lightning being sulfurous is a very ancient belief, mentioned by ancient Roman authors and present in the works of Homer, where descriptions of the divine lightning of Zeus mention sulfur several times (in the Iliad, it strikes in front of the horses of Diomedes, causing a smell of sulfur and flames, at another point, Hector is compared to an oak uprooted by Zeus' lightning, smelling of sulfur, while in the Odyssey, it strikes a ship, filling it with sulfurous smoke). The 18th century theologian Jonathan Edwards considered lightning to be "a string of brimstone". Lightning does not actually contain sulfur or produce sulfur odorants. Ozone would later be identified, in the 19th century, as the element behind the smell of lightning, but even then, people unfamiliar with ozone were said to still commonly misidentify the smell as brimstone.

Sources: en.wikipedia.org

Reference notes

=== 2008–2011: Black Gives Way to Blue and death of Mike Starr === Blabbermouth.net reported on September 5, 2008, that Alice in Chains would enter the studio that October to begin recording a new album for a summer 2009 release. On September 14, 2008, Alice in Chains performed at halftime during the Seattle Seahawks vs San Francisco 49ers game at the Qwest Field (now named Lumen Field ) in Seattle. The 12-minute performance for a crowd of 67,000 people featured a cover of Led Zeppelin's "Kashmir" accompanied by the Northwest Symphony Orchestra. In October 2008, Alice in Chains began recording its fourth studio album at the Foo Fighters' Studio 606 in Los Angeles with producer Nick Raskulinecz. The band did not have a record label at the time and the album was funded by Jerry Cantrell and Sean Kinney. At the Revolver Golden God Awards, Cantrell said that the group had finished recording on March 18, 2009, and were mixing the album for a September release. The recording process was completed on Cantrell's 43rd birthday and also the same day that William DuVall's son was born. In April 2009, it was reported that the new Alice in Chains album would be released by Virgin/EMI, making it the band's first label change in its 20-plus year career. David Benveniste and his Velvet Hammer Music & Management Group began co-managing the band with Susan Silver, marking the most recent change of management and latest development to date.

==== Early 1990s ==== The Virgilio Barco Vargas (1986–1990) administration, in addition to continuing to handle the difficulties of the complex negotiations with the guerrillas, also inherited a particularly chaotic confrontation against the drug lords, who were engaged in a campaign of terrorism and murder in response to government moves in favor of their extradition overseas. In June 1987, the ceasefire between FARC and the Colombian government formally collapsed after the guerrillas attacked a military unit in the jungles of Caquetá. According to journalist Steven Dudley, FARC founder Jacobo Arenas considered the incident to be a "natural" part of the truce and reiterated the group's intention to continue the dialogue, but President Barco sent an ultimatum to the guerrillas and demanded that they immediately disarm or face military retaliation. Regional guerrilla and Army skirmishes created a situation where each violation of the ceasefire rendered it null in each location, until it became practically nonexistent. By 1990, at least 2,500 members of the FARC-founded Patriotic Union had been murdered, according to historian Daniel Pecáut, which led up to that year's assassination of presidential candidate Bernardo Jaramillo Ossa.

== Diagnostic testing == Numerous studies confirming a strong correlation between elevated Lp(a) and heart disease have led to the consensus that Lp(a) is an important independent predictor of cardiovascular disease. Animal studies have shown that Lp(a) may directly contribute to atherosclerotic damage by increasing plaque size, inflammation, instability, and smooth muscle cell growth. Genetic data also support the theory that Lp(a) causes cardiovascular disease. The European Atherosclerosis Society recommends that patients with a moderate or high risk of cardiovascular disease should have their Lp(a) levels checked. Any patient with one of the following risk factors should be screened:

Sources: en.wikipedia.org

Reference notes

Mirroring the upwards trend in the volume of opioid pain relievers prescribed was an increase in admissions for substance use disorder treatments and opioid-related deaths. This illustrates how legitimate clinical prescriptions of pain relievers were being diverted through an illegitimate market, leading to misuse, addiction, and death. With the increase in volume, the potency of opioids also increased. By 2002, one in six opioid users was prescribed drugs more powerful than morphine. By 2012, the ratio had doubled to one in three. The most commonly prescribed opioids were oxycodone and hydrocodone.

=== Winemaking and fungal source chitosan === Chitosan has a long history for use as a fining agent in winemaking. Fungal source chitosan has shown an increase in settling activity, reduction of oxidized polyphenolics in juice and wine, chelation and removal of copper (post-racking) and control of the spoilage yeast Brettanomyces. These products and uses are approved for European use by the EU and OIV standards.

Kimchi (; Korean: 김치; pronounced [kim.tɕʰi]) is a traditional Korean side dish (banchan) consisting of salted and fermented vegetables, most often Chinese cabbage or Korean radish. A wide selection of seasonings are used, including gochugaru (Korean chili powder), spring onions, garlic, ginger, and jeotgal (salted seafood). Kimchi is also used in a variety of soups and stews. Kimchi is a staple food in Korean cuisine and is eaten as a side dish with almost every Korean meal. There are hundreds of different types of kimchi made with different vegetables as the main ingredients. Examples of variants include baechu-kimchi, kkakdugi, chonggak-kimchi, and oi-sobagi. Traditionally, winter kimchi, called gimjang, was stored in large earthenware fermentation vessels, called onggi, in the ground to prevent freezing during the winter months and to keep it cool enough to slow down the fermentation process during summer months. The process of making kimchi was called gimjang and was based on participation by the whole village. The vessels are also kept outdoors in special terraces called jangdokdae. The use of household kimchi refrigerators has become a more common method for keeping fermenting kimchi at the right temperature. Kimchi has gained international recognition as a traditional Korean food and has been promoted as part of Korean cultural heritage. Its preparation methods and cultural significance have been documented as part of Korea's intangible cultural heritage.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Why is AOD-9604 banned in sports?

The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.

Does AOD-9604 raise growth hormone levels?

It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network